CRC Research Update — October 01, 2026
Today's colorectal cancer research highlights
Curated CRC research, accessible, accurate, actionable
The CRC Digest
Thursday, October 01, 2026
IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.
CRC Research Update
-
SCREENING
US Task Force Issues Consensus Statement on Serrated Polyposis SyndromeThe US Multi-Society Task Force on Colorectal Cancer released new guidance on serrated polyposis syndrome (SPS), the most common polyposis syndrome, which often goes unrecognized despite conferring increased risk of colorectal cancer. The consensus recommends meticulous inspection, clearing of the colon, and frequent surveillance colonoscopy to decrease incident CRC. (Gastroenterology)
-
SCREENING
Quantitative FIT Values May Help Triage Colonoscopy in Resource-Constrained SettingsA commentary in Cancer Epidemiology, Biomarkers & Prevention highlights how quantitative fecal immunochemical testing (qFIT) can provide a more refined measure of fecal hemoglobin than binary positive/negative results, potentially helping manage limited colonoscopy resources by stratifying subsequent colorectal cancer risk. (Cancer Epidemiology, Biomarkers & Prevention)
-
TREATMENT
OSERO Study Examines Treatment Sequencing of Regorafenib and FTD/TPI in Metastatic CRCThe OSERO study was a prospective observational study in patients with metastatic colorectal cancer scheduled for later-line treatment with regorafenib or trifluridine/tipiracil (FTD/TPI), with or without bevacizumab. (British Journal of Cancer)
-
LIVING WITH CRC
Case Report Describes Delayed, Multisystem Immune Side Effects After Nivolumab Plus IpilimumabA patient with MSI-high colon cancer developed adrenocorticotropic hormone deficiency during combination immunotherapy and, six months after the final nivolumab dose, presented with bilateral knee arthritis and elevated hepatobiliary and pancreatic enzymes, illustrating that immune-related adverse events can occur long after treatment discontinuation. (Clinical Journal of Gastroenterology)
Today's research spans screening guidance, treatment sequencing in advanced disease, and biomarker discovery across diverse populations.
Get CRC research intelligence delivered weekly, free.
SubscribeCRC Digest
Not Medical Advice
The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.
Content is curated with AI assistance and reviewed by the editorial team.
Browse Past Issues · Read our full disclaimer · Manage subscription
Useful? Forward it to a colleague. Many of the topics named here have a live research dossier, trajectory and evidence, at Signal Bureau.
Got this from a colleague? Subscribe here. We only ever add readers who sign themselves up.
Evolution Accelerator, Inc. (dba Evolution Labs) · 3941 Park Dr., Suite 20341, El Dorado Hills, CA 95762
You are receiving this because you subscribed to CRC Digest (self-serve signup)
Unsubscribe: honored promptly, no login required. · Privacy policy · Manage or delete your data